Welcome to our dedicated page for Medifast SEC filings (Ticker: MED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Overview of Medifast Inc (MED)
Medifast Inc is a well-established company in the health and wellness industry, renowned for its clinically proven nutrition and weight loss solutions. Founded with strong medical expertise, the company has served as a trusted resource for individuals seeking to manage weight and embrace healthier lifestyles. With a foundation in physician-developed programs, Medifast is distinguished by its holistic, habit-based, and coach-guided approach that integrates nutrition, behavioral modification, and community support into a comprehensive solution.
Comprehensive Nutrition and Weight Loss Solutions
Medifast provides an extensive range of programs designed to address the multifaceted challenges of weight management and lifestyle transformation. Key industry keywords such as nutrition, weight loss, and wellness are embedded at the core of its offerings. The company tailors its solutions to meet varied health needs, offering personalized support for those looking to overcome obesity and foster sustainable lifestyle changes. This attention to individual goals is achieved through:
- Clinically Validated Programs: Each solution is developed with a strong clinical foundation, ensuring that nutritional and weight loss strategies are based on medical research and proven methodologies.
- Coach-Guided Support: Medifast believes that effective transformation is best supported by continuous coaching and personalized guidance, ensuring that every client has access to expert advice and motivational support.
- Habit-Based Lifestyle Change: Recognizing that lasting transformation requires more than just diet changes, Medifast focuses on creating sustainable healthy habits that integrate smoothly into everyday life.
- Community Integration: Through peer support and group engagement, the company fosters a sense of community, allowing individuals to share experiences, challenges, and successes on their journey toward optimal wellness.
Core Business Model and Revenue Streams
Medifast's business model is built around the direct sale of clinically formulated weight loss and nutritional products, coupled with subscription-based services that offer continuous access to coaching and personalized nutrition plans. By integrating direct product sales with supportive coaching programs, the company generates revenue through a balanced mix of one-time purchases and ongoing customer relationships. This dual approach ensures that both immediate and long-term customer needs are met while reinforcing the company’s reputation for efficacy and reliability.
Integration of Medical Science and Personalized Guidance
At its heart, Medifast is more than just a weight loss company; it is a comprehensive health solutions provider. The programs are rooted in clinical evidence and developed under the guidance of medical professionals, ensuring that each plan is safe, targeted, and effective. Medifast is known for pioneering innovative solutions such as its OPTAVIA program, where personalized coaching, structured nutritional planning, and a focus on behavioral change converge into a single, integrated wellness platform. Moreover, the company incorporates advanced clinical methodologies, including the appropriate use of GLP-1 medications in contexts where such interventions enhance the weight loss process, always ensuring that clinical judgment and safety are prioritized.
Market Position and Industry Relevance
Operating within the competitive landscape of health and wellness, Medifast has carved out a niche as a company that skillfully blends scientific rigor with empathetic, personalized support. Its longstanding recommendation by thousands of doctors and its proven record of success underscore its commitment to quality and reliability. The company positions itself as a resource for those seeking not just temporary weight loss but a lifelong transformation, where the journey toward a healthier life is supported by expert guidance every step of the way.
Strategic Focus on Lifelong Transformation
Medifast's vision is founded on the belief that genuine well-being emerges when individuals are empowered to take control of their health. By providing multifaceted support that includes nutritional guidance, behavioral coaching, and community involvement, the company ensures that clients are equipped with the tools necessary to make healthy living second nature. The emphasis on lifelong transformation is evident in every aspect of its operations, from the development of new, evidence-based programs to ongoing enhancements in client engagement and support. This strategic focus on enduring lifestyle change not only reaffirms its market significance but also builds a robust foundation of trust and authority among its users and healthcare partners.
Quality, Safety, and Expert Backing
Every program and product offered by Medifast is a result of in-depth research, expert consultation, and rigorous testing. The company maintains an unwavering commitment to safety and quality, ensuring that all nutritional products meet high clinical standards. This dedication is mirrored in the personalized coaching and support structures that are essential to achieving the desired outcomes. The systematic integration of scientific insights with user-centric approaches makes Medifast a trusted name for both individuals and healthcare professionals.
Conclusion
Overall, Medifast Inc represents a holistic lifestyle solution that successfully merges clinical expertise with personalized, coach-guided support. Its integrated approach to weight loss, coupled with a mission to make healthy lifestyle changes accessible and sustainable, positions the company as a crucial player in the health and wellness industry. The firm not only addresses the immediate challenges of weight management but also lays the groundwork for lifelong well-being by empowering individuals to transform their habits and embrace a healthier future.
Medifast Director Xian Ming received two grants of Restricted Stock Units (RSUs) on June 25, 2025:
- 11,167.65 cash-settled RSUs as part of director compensation, vesting fully on June 25, 2026
- 6,013.35 additional RSUs valued at $13.39 per share (based on 20-day moving average), elected in lieu of cash compensation
Both RSU grants will be payable in cash upon Ming's termination of service as director. Following these transactions, Ming beneficially owns 26,129.568 RSUs from the first grant and 32,142.918 RSUs from the second grant. The RSUs were granted under Medifast's Director's Deferred Compensation Plan and the Amended and Restated 2012 Share Incentive Plan.
Medifast Director Scott Schlackman received 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and represent the right to receive an equivalent number of common shares.
Key details of the transaction:
- The RSUs will fully vest on June 25, 2026
- Shares are granted under the Amended and Restated 2012 Share Incentive Plan
- Following the transaction, Schlackman owns 25,548.707 shares directly
- The grant is part of annual director compensation
The Form 4 was filed through an attorney-in-fact, Jason L. Groves, on June 26, 2025, within the required reporting timeline for insider transactions.
Director Andrea B Thomas of Medifast received 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the Director's Deferred Compensation Plan. The RSUs were granted under the company's Amended and Restated 2012 Share Incentive Plan.
Key details of the transaction:
- RSUs were granted at $0 cost to the director
- Each unit represents one share of Medifast common stock
- Full vesting scheduled for June 25, 2026
- Following the transaction, Thomas owns 24,017.123 shares directly
This grant represents standard director compensation rather than an open market transaction. The filing was submitted by attorney-in-fact Jason L. Groves on June 26, 2025, within the required reporting timeframe.
Director Michael A. Hoer of Medifast received a significant equity grant of 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and will fully vest on June 25, 2026.
Key details of the transaction:
- Each RSU represents the right to receive one share of Medifast common stock
- The grant was made under the Amended and Restated 2012 Share Incentive Plan
- Following the transaction, Hoer owns 26,139.473 shares directly
- The RSUs were granted in connection with annual director compensation
This Form 4 filing, signed by attorney-in-fact Jason L. Groves, indicates continued alignment of director interests with shareholders through equity-based compensation.
Medifast director Elizabeth A. Geary received 11,168 restricted stock units (RSUs) on June 25, 2025 as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and will fully vest on June 25, 2026.
Key details:
- Each RSU represents the right to receive one share of Medifast common stock
- The grant was made under the Amended and Restated 2012 Share Incentive Plan
- Following the transaction, Geary directly owns 19,545 shares
- The RSUs were granted in connection with annual director compensation
This Form 4 filing indicates standard director equity compensation practices at Medifast, with a one-year vesting period for director RSU grants.
Medifast Director Jeffrey J. Brown reported significant stock acquisitions on June 25, 2025, through multiple transactions:
- Received 11,167.542 restricted stock units under the Director's Deferred Compensation Plan, which will fully vest on June 25, 2026
- Acquired 9,449.458 shares of common stock at $13.39 per share in lieu of cash compensation for director services
Following these transactions, Brown's total beneficial ownership includes:
- 38,577.647 shares held directly
- 4,232.967 shares held indirectly through the Jeffrey Brown Living Trust
The stock price was calculated using the 20-day moving average as of June 6, 2025. This Form 4 filing demonstrates significant insider accumulation of shares through compensation arrangements, suggesting continued alignment with shareholder interests.
Medifast, Inc. (NYSE: MED) filed an 8-K reporting the results of its 2025 Annual Meeting held on June 18, 2025.
Equity plan expansion: Shareholders approved an amendment to the Amended and Restated 2012 Share Incentive Plan, authorizing an additional 550,000 common shares for future equity awards. The plan became effective immediately and its full text is attached as Exhibit 10.1.
Board elections: All seven incumbent directors were re-elected. Support ranged from 90.3 % (Andrea B. Thomas) to 97.2 % (Jeffrey J. Brown) of votes cast, with 2.09 million broker non-votes recorded for each nominee.
Auditor ratification: RSM US LLP was ratified as independent auditor for FY 2025 with 99.2 % of votes in favor (8,225,570 for / 39,619 against).
Say-on-pay advisory vote: Compensation for named executive officers passed but with a modest margin—3,585,469 for vs. 2,477,849 against (59.1 % support, excluding abstentions).
Plan approval vote: The amended share incentive plan itself received 5,518,075 for vs. 664,416 against (88.2 % support, excluding abstentions).
No other material transactions, earnings data, or financial statements were disclosed.
FAQ
What is the current stock price of Medifast (MED)?
What is the market cap of Medifast (MED)?
What is Medifast's primary business offering?
How does Medifast generate its revenue?
What distinguishes Medifast from other weight loss companies?
Can you explain the OPTAVIA program?
How does Medifast integrate clinical science into its programs?
Who are the typical customers of Medifast?
How does Medifast support long-term health and wellness?
What role do GLP-1 medications play in Medifast's offerings?
